Holen Sie sich die Stockscreener-App
5.78
0.87%
0.05
Vorhandelsmarkt:
5.68
-0.10
-1.73%
Schlusskurs vom Vortag:
$5.73
Offen:
$5.53
24-Stunden-Volumen:
639.21K
Relative Volume:
0.65
Marktkapitalisierung:
$267.76M
Einnahmen:
$20.72M
Nettoeinkommen (Verlust:
$-100.84M
KGV:
-2.1729
EPS:
-2.66
Netto-Cashflow:
$-78.56M
1W Leistung:
+28.44%
1M Leistung:
+46.33%
6M Leistung:
-3.18%
1J Leistung:
-60.71%
1-Tages-Spanne:
$5.4204
$5.845
1-Wochen-Bereich:
$4.99
$6.69
52-Wochen-Spanne:
$2.235
$17.41
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Vergleichen Sie FDMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
5.78 | 265.44M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
375.63 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.80 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.10 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
672.35 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.29 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2024-09-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Eingeleitet | Barclays | Overweight |
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
Will earnings trigger a reversal in 4D Molecular Therapeutics Inc.Volume Spike Detection for Early Breakouts - Newser
Heatmap analysis for 4D Molecular Therapeutics Inc. and competitors7-Day Equity Return Range Forecast Model - Newser
What makes 4D Molecular Therapeutics Inc. stock attractive to long term investorsFree Real Market Momentum Signal Generator - Newser
Published on: 2025-08-07 03:01:11 - Newser
4D Molecular Therapeutics (FDMT) to Release Earnings on Thursday - Defense World
4D Molecular Therapeutics shares fall 2.73% intraday after announcing participation in H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
Volatility clustering patterns for 4D Molecular Therapeutics Inc.Short-Term Sector Movement Forecast Generator - Newser
Using fundamentals and technicals on 4D Molecular Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser
Developing predictive dashboards with 4D Molecular Therapeutics Inc. dataEquity Portfolio Outlook and Performance Summary - Newser
4D Molecular Therapeutics Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
How to build a custom watchlist for 4D Molecular Therapeutics Inc.Entry Opportunity Screener with Confirmation - Newser
Fibonacci Support Holding Strong in 4D Molecular Therapeutics Inc.Conservative Long Term Growth Plans Under Review - beatles.ru
Why is 4D Molecular Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent profits with proven methods - Jammu Links News
4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at Chardan Capital - Defense World
Is 4D Molecular Therapeutics Inc. a growth stock or a value stockProven strategies for superior portfolio growth - Jammu Links News
What is the dividend policy of 4D Molecular Therapeutics Inc. stockGet daily expert analysis on top stocks - Jammu Links News
Is 4D Molecular Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Capital Preserving Trade Plan Templates - Newser
What is the risk reward ratio of investing in 4D Molecular Therapeutics Inc. stockExplosive capital gains - Jammu Links News
What are 4D Molecular Therapeutics Inc. company’s key revenue driversCapitalize on fast-growing investment opportunities - Jammu Links News
Does 4D Molecular Therapeutics Inc. stock perform well during market downturnsRapid profit acceleration - Jammu Links News
Is 4D Molecular Therapeutics Inc. stock overvalued or undervaluedInvest smarter with data-backed trading alerts - Jammu Links News
What are the technical indicators suggesting about 4D Molecular Therapeutics Inc.Spectacular growth rates - Jammu Links News
When is 4D Molecular Therapeutics Inc. stock expected to show significant growthMassive stock growth - Jammu Links News
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionFree Low Risk Swing Trade Opportunity List - Newser
4D Molecular Therapeutics Inc. stock prediction for this weekLow Drawdown Picks with Weekly Updates - Newser
4D Molecular Therapeutics Showcases Positive Trial Results, Charts New Growth Trajectory - timothysykes.com
4D Molecular (FDMT) Stock Climbs Following Promising Retina Therapy Data - Stocks Telegraph
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study - 富途牛牛
How volatile is 4D Molecular Therapeutics Inc. stock compared to the marketEntry Signal Forecasts With Low Risk - Jammu Links News
4D Molecular: Time to Buy After Recent Surge? - StocksToTrade
4D Molecular Therapeutics: A Market Shift? - timothysykes.com
4D Molecular Therapeutics shares rise 30.44% premarket after presenting positive 60-week results for 4D-150. - AInvest
Chardan Capital Maintains Buy on 4D Molecular, Raises PT to $25 - AInvest
4D Molecular Therapeutics stock soars after positive DME trial results By Investing.com - Investing.com Canada
Will a bounce in 4D Molecular Therapeutics Inc. offer an exitPrice Action Trading with Volume Confirmation - Newser
4D Molecular Therapeutics Shares Surge 50.89% on Positive Clinical Trial Results - AInvest
4D Molecular Therapeutics (FDMT) Shares Soar 37.78% on Positive Clinical Trial Results - AInvest
4D Molecular Therapeutics shares rise 56% premarket after presenting positive 60-week results for 4D-150. - AInvest
4D Molecular (FDMT) Shows Promising Results in Clinical Trial fo - GuruFocus
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update - GlobeNewswire
How does 4D Molecular Therapeutics Inc. compare to its industry peersBeginner Investor Strategy With Proven Results - Jammu Links News
Trend Reversal Possible in 4D Molecular Therapeutics Inc. Charts IndicateEarnings Play Trade Plan With Alerts Shared - beatles.ru
Advanced analytics toolkit walkthrough for 4D Molecular Therapeutics Inc.Real Time Trade Execution Alert Plan - Newser
Weiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Published on: 2025-07-29 16:44:26 - Newser
How 4D Molecular Therapeutics Inc. stock performs during market volatilityPortfolio Positioning Strategy With Timing - Newser
What makes 4D Molecular Therapeutics Inc. stock price move sharplyMinimal Risk Growth Investment Opportunity Analysis - Newser
4D Molecular Therapeutics Bets Big On Gene Therapy Breakthroughs - Finimize
Published on: 2025-07-29 09:03:48 - metal.it
Published on: 2025-07-29 02:38:48 - metal.it
Trapped Investors in 4D Molecular Therapeutics Inc. Await Breakout SignalTriple Digit Return Stock Predictions Released - metal.it
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):